Clinical trials: Zoledronic Acid
Leukemia, Lymphoma
Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant
RATIONALE: Zoledronic acid, vitamin D, and calcium may prevent bone loss in patients who are undergoing donor stem cell transplant.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis
- Trial name
- NCT00321932
- Testing
- calcium, cholecalciferol, zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Minnesota
Multiple Myeloma and Plasma Cell Neoplasm
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
RATIONALE: Zoledronate may prevent bone loss and stop the growth of cancer cells in bone. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer.
- Trial name
- NCT00432458
- Testing
- Thalidomide, zoledronic acid
- Where
- 4 sites in United States
- Volunteers
- 68 people
- Sponsor
- Mayo Clinic
Bone Loss
Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss
This is a double-blind, randomized, placebo-controlled trial of zoledronic acid, 5mg, to be administered intravenously to people who have suffered an acute spinal cord fracture.
- Trial name
- NCT00844480
- Testing
- zoledronic acid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Thomas J. Schnitzer
Osteoporosis
Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis
The aim of this study was to examine the effect of zoledronic acid and alendronate on bone metabolism as measured by biomarkers in postmenopausal women with osteoporosis.
- Trial name
- ROSE (NCT00404820)
- Testing
- Zoledronic acid 5 mg solution, Alendronate 70 mg tablets, Calcium/Vitamin D
- Where
- Germany
- Volunteers
- 604 people
- Sponsor
- Novartis
Paget's Disease of the Bone
Re-treatment of Participants With Paget's Disease Using Zoledronic Acid
The purpose of this study was to demonstrate that participants with Paget's disease of the bone who had responded to zoledronic acid treatment as participants in the core registration studies CZOL446K2304 and CZOL446K2305 and…
- Trial name
- NCT00740129
- Testing
- Zoledronic Acid
- Where
- 11 sites in Belgium, Canada and 4 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Bariatric Surgery Candidate
Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric Surgery
This study evaluates whether zoledronic acid can prevent the high bone turnover that occurs after Roux-en-Y Gastric Bypass (RYGB) and sleeve gastrectomy (SG) surgery.
- Trial name
- NCT03424239
- Testing
- Zoledronic Acid, Calcium citrate + vitamin D, Vitamin D3
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Massachusetts General Hospital
Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women
A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss
Breast cancer and osteoporosis are two of the most frequent diseases in women. Estrogen may be associated with bone loss and the risk of breast cancer because of its potent effects on the mitotic activity of breast epithelium and…
- Trial name
- NCT00333229
- Testing
- Zoledronic Acid
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids
This study was designed to evaluate the efficacy and safety of zoledronic acid compared to placebo in osteoporotic children treated with glucocorticoids
- Trial name
- NCT00799266
- Testing
- Zoledronic acid
- Where
- 12 sites in Australia, Canada and 4 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Spinal Cord Injury
Zoledronic Acid in Acute Spinal Cord Injury
Maintenance of bone mass following spinal cord injury (SCI) is essential to fracture prevention and the associated morbidity of bed rest and further secondary complications.
- Trial name
- NCT01642901
- Testing
- Zoledronic acid, normal saline 0.9%
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Thomas Jefferson University
Prostate Cancer
PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
The primary goal for this trial is to assess the change in PET scans with the administration of zoledronate (bisphosphonate) therapy in patients with metastatic prostate cancer.
- Trial name
- NCT01205646
- Testing
- zoledronate therapy, PET Scan
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Renal Insufficiency
Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants
The study is designed to look at the effect of different bone treatment plans on bone loss after kidney or kidney/pancreas transplant.
- Trial name
- NCT00580047
- Testing
- Zoledronic Acid, Calcium with vitamin D, Alendronate
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- University of Nebraska
Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
RATIONALE: Zoledronic acid may prevent bone loss and help prevent or lessen musculoskeletal symptoms in women receiving hormone therapy for breast cancer.
- Conditions
- Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer
- Trial name
- NCT01194440
- Testing
- letrozole, zoledronic acid
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
The purpose of this study is to describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received either…
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00950911
- Testing
- amg 162
- Where
- 17 sites in Czechia, United Kingdom
- Volunteers
- 35 people
- Sponsor
- Amgen
Breast Cancer
The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every…
- Trial name
- NCT00171314
- Testing
- Zoledronic acid, Letrozole
- Where
- 49 sites in Argentina, Belgium and 7 more
- Volunteers
- 527 people
- Sponsor
- Novartis Pharmaceuticals
Breast Neoplasms, Osteoporosis
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
This protocol is designed to compare the effect on bone of Zoledronic Acid 4 mg every 6 months when given upfront versus delayed start (based on a post-baseline BMD T- Score below -2.0 SD at either the lumbar spine or total hip…
- Trial name
- NCT00050011
- Testing
- Zoledronic Acid, Letrozole
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 602 people
- Sponsor
- Novartis Pharmaceuticals
First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
This study will evaluate zoledronic acid's anti-cancer effects and Circulating Tumor Cell (CTCs) measurements in patients with HER2-negative metastatic breast cancer without bone metastasis.
- Trial name
- MACS1295 (NCT01129336)
- Testing
- Zoledronic acid, Standard Therapy
- Where
- 33 sites in United States
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Cancer, Hematologic Malignancies
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone disease from multiple myeloma.
- Conditions
- Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology
- Trial name
- NCT01345019
- Testing
- Denosumab, Zoledronic acid, Denosumab (for the open-label treatment phase)
- Where
- 309 sites in United States, Australia and 27 more
- Volunteers
- 1,718 people
- Sponsor
- Amgen
Multiple Myeloma
Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)
Investigators planned to accrue 176 participants, to compare the response rate, overall response rate and survival of patients with multiple myeloma (MM) when randomized to two regimens (thalidomide+Dexamethasone versus…
- Trial name
- NCT00215943
- Testing
- zoledronic acid, dexamethasone, thalidomide
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 90 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Progeria, Hutchinson-Gilford Syndrome
A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
This is an open label single arm feasibility trial. A combination of two oral agents (pravastatin and lonafarnib) and one intravenous (IV) agent (zoledronic acid) will be administered at doses and schedule currently applied in…
- Trial name
- NCT00879034
- Testing
- Lonafarnib, Zoledronic Acid, Pravastatin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Boston Children's Hospital
Post-menopausal Osteoporosis
3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
This second extension will evaluate the efficacy and long term safety of zoledronic acid in women with post-menopausal osteoporosis
- Trial name
- NCT00718861
- Testing
- Zoledronic acid
- Where
- 57 sites in United States, Argentina and 16 more
- Volunteers
- 190 people
- Sponsor
- Novartis Pharmaceuticals